Replies to post #137364 on Biotech Values

[iwfal]

HCV DAA Treatment

Also, all 10 nulls achieved RVR. Another possible point is that in PROTON trial all 13 GT1 patients with genotype TT in IL28B (IFN poor responders), achieved RVR and SVR12.

Thank you very much for the explanation (truly). It was a puzzle to me - but with your explanation I think it is explained as yet another example of the widely accepted, but odd (to my mind), perception that a good individual DAA is inherently 'just better' than interferon.

As I have noted numerous times before, I wish there were some way to make money on this group think. I'd also love to be able to figure out where it is coming from (in a Kahneman sense).